IMARC Group, a leading market research company, has recently releases report titled “Digital PCR Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global digital PCR market report, growth, share, size, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Industry Overview of Digital PCR Market

Digital PCR (dPCR) is a highly sensitive molecular biology technique used to quantify and analyze nucleic acids, such as DNA or RNA, in a sample. It partitions the sample into numerous individual reactions, each containing a small number of target molecules. By amplifying and detecting the target molecules within these partitions, dPCR enables precise quantification of the nucleic acids present. This technology offers advantages in terms of its ability to detect rare genetic variants, accurately measure gene expression levels, and provide absolute quantification without the need for external standards. With its high sensitivity and reproducibility, dPCR finds applications in research areas such as genomics, cancer diagnostics, infectious disease detection, and liquid biopsies.

How Big Is the Digital PCR Market?

The global digital PCR market size reached US$ 4.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.9 Billion by 2028, exhibiting a growth rate (CAGR) of 10.5% during 2023-2028.

Global Industry Trends and Drivers:

The digital PCR (dPCR) market is driven by various industry trends and drivers that contribute to its growth and expansion. One significant trend is the increasing adoption of precision medicine and personalized diagnostics. dPCR provides a highly sensitive and accurate method for quantifying nucleic acids, making it valuable in detecting and monitoring genetic variations and mutations associated with diseases. This aligns with the growing demand for precise and targeted therapies, driving the uptake of dPCR technology in healthcare. Another driver is the rising prevalence of infectious diseases and genetic disorders. dPCR's ability to detect and quantify low abundance nucleic acid targets enables early diagnosis and monitoring of diseases, leading to improved patient outcomes. Additionally, the advancements in genomics research and the need for better understanding of genetic variations fuel the demand for dPCR technologies, as they offer higher resolution and sensitivity compared to traditional PCR methods.

The increasing focus on non-invasive liquid biopsies is also driving the market. dPCR plays a crucial role in analyzing and detecting genetic biomarkers present in circulating tumor DNA or cell-free DNA, facilitating early cancer detection, monitoring treatment response, and disease progression. This non-invasive approach is gaining traction as an alternative to invasive tissue biopsies, and dPCR is a key enabling technology in this field.

What Is Included In Market Segmentation?

The report has been segmented the market into following categories:

Breakup by Product Type:

• Digital PCR Equipment
• Consumables and Reagents
• Software and Services
   

Breakup by Technology:

• Droplet Digital PCR
• BEAMing Digital PCR
   

Breakup by Application:

• Clinical Diagnostics
• Forensics
• Research
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report provides a comprehensive analysis of the industry key players listed below:

Avance Biosciences Inc., Bio-Rad Laboratories Inc., Danaher Corporation, JN Medsys, OPTOLANE Technologies Inc., QIAGEN, SAGA Diagnostics AB, Standard BioTools Inc., Stilla Technologies, Sysmex Corporation and Thermo Fisher Scientific Inc.